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DCIS comprises approximately 20-25% of all ‘breast cancers’ 
detected by mammographic screening programs. Such programs 
were set up to identify early invasive disease so the large numbers 
of all grades of DCIS diagnosed were unforeseen, unexpected and 
unwelcome. As the natural history of untreated DCIS is largely 
unknown, its management is controversial; mammogram detected 
DCIS is usually treated as if it is cancer, primarily with surgery. 
Adjuvant treatments may also be offered which vary from hospital 
to hospital and from country to country (1). Surgery for DCIS has 
remained largely unchanged since the 1970s and mastectomy is 
now performed more often than is seen with invasive cancer. It is 
40 years since the inception of the first breast screening programs 
and time to question the appropriateness and the outcomes of 
these management policies for screen-detected DCIS.  
Sagara and colleagues have scrutinized SEER data from 9 US states 
involving 57222 women with a median 72 months follow-up from 
diagnosis (2). They showed that the vast majority of patients 
diagnosed with all grades of DCIS who did not receive surgery did 
not die from breast cancer. Of those patients who received surgery, 
29% had a mastectomy.  Among patients diagnosed with low-grade 
DCIS, the weighted 10-year breast cancer–specific survival of the 
non-surgery group was 98.8% and for patients having surgery 
98.6% (P = 0.95). Multivariate analysis also showed no significant 
difference in the weighted hazard ratios of breast cancer–specific 
survival between the surgery and non-surgery groups for low-grade 
DCIS. There was also no overall survival benefit for patients with 
low grade DCIS who had surgery compared to those who did not.  
 
The authors eloquently describe both the use of propensity score 
weighting and elucidate other potential problems in their paper such 
as limited information regarding patient characteristics and surgical 
margins etc., but flaws notwithstanding, it seems more likely than 
not that we have been getting the treatment of low grade DCIS 
wrong. Past management may have been determined with the best 
of intentions, but for several years now many clinicians, 
pathologists, statisticians and others have voiced genuine concern 
about the likely over-treatment of screen detected DCIS. Although 
independent reviews of screening programs (3) concur that 
overtreatment exists, statisticians and epidemiologists do not agree 
about its magnitude and produce varying estimates (4). This leaves 
women of screening age, patients and their surgeons with a 
dilemma that must be resolved with better prospective evidence 
gathered from multidimensional, comprehensive studies. This might 
not be easy but with more women themselves recognising the 
controversies surrounding DCIS (5) clinicians do need to design 
prospective randomised trials of active monitoring with translational 
questions. This would give patients have access to a ‘plan B’, 
namely trial participation, if they are unsure about surgery. 
 
The call by Sagara et al for a prospective clinical trial of active 
surveillance of low grade DCIS in the US might prove challenging, 
but as surgical equipoise is essential for successful trial recruitment, 
addressing initially the overtreatment of patients with Low Grade 
DCIS might be the best strategy to gain surgeons’ acceptance and 
engagement.  
 
A unique environment exists within the UK enabling successful 
recruitment to such trials. The UK clinical culture is not quite as 
‘risk-averse’ as that in the US, and only a minority of the UK 
population receive screening or their medical treatment through 
insurance. This combination of factors permits more likelihood of 
enrolment in trials that offer patients ‘less’ treatment despite this 
area being recognised as a difficult one for patients and doctors 
alike.  
 
The National Institute for Health Research Health Technology 
Assessment (NIHR, HTA) Program has recently supported the Low 
Risk DCIS Study (LORIS) http://www.birmingham.ac.uk/loris. This 
important trial, driven by clinicians in partnership with patients from 
Independent Cancer Patients Voice (ICPV), opened its feasibility 
phase in 2014. LORIS aims to enrol 932 patients with ‘Low Risk’ 
DCIS to standard treatment or active monitoring. Current 
recruitment is on target and shows yet again that women with 
‘breast cancer’ are brave, well informed & altruistic.  
 
Such trials demand thoughtful planning before funding; in LORIS, 
the focus groups held with women who regularly attended for 
mammographic screening were invaluable and showed 
unequivocally that they needed the facts and uncertainties 
associated with DCIS communicated(6). A majority welcomed an 
opportunity to participate in a trial addressing the issues. They 
highlighted the potential confusions caused by the terminology, so a 
survey of health care professionals was conducted to determine the 
best nomenclature to use in the trial when discussing DCIS (7). 
Finally a DVD for women considering trial entry was made; this 
explains the rationale and logic for the study in the even handed 
manner demanded for such a controversial topic and which many 
clinicians find challenging.  
 
Active monitoring within LORIS requires large volume core biopsies 
and a real time central pathology review by expert DCIS 
pathologists from the UK National Sloane project to ensure that only 
patients with low grade features are enrolled. Further safety 
features incorporate inclusion criteria designed to exclude women at 
higher risk of having accompanying higher grade disease, such as 
the absence of a mass lesion clinically and on imaging. All patients 
are followed up with annual mammography and appropriate Patient 
Reported Outcomes and health economic questions are embedded 
within the protocol. Pivotal to the trial is collection of tissue for 
translational work and both tissue and imaging banks will provide 
unique future resources.  
 
The publication by Sagara and colleagues has provided an 
important platform on which, as they suggest, clinical trials of 
active monitoring can be successfully built. As the recent Time 
magazine headline story shows there are surgeons and patients 
across the US ready to address these difficult issues. Women taking 
part in such studies will allow future generations worldwide to make 
informed choices based on data that currently are unavailable. 
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